Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose glucocorticoid prophylaxis for serum sickness after ATG/ALG in aplastic anemia
ChiCTR2400087735Phase 3Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of methylprednisolone in aplastic anemia and serum sickness (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Incidence of serum sickness. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
methylprednisolone
03
Conditions
aplastic anemiaserum sickness
Beyond the preview
Go deeper on ChiCTR2400087735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087735.